香蕉视频

Mycobacterial lung infections are caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria (NTM). Antimicrobial therapy is the cornerstone of mycobacterial lung infection management. It can be used as a preventive therapy and treatment of active disease. However, the emergence of drug-resistant mycobacteria and the use of suboptimal regimens to treat mycobacterial lung infections jeopardize the ability to treat these infections. Therefore, understanding the mechanisms causing antimicrobial resistance and optimizing new drugs or regimens to fight drug-resistant bacteria are essential to effectively treat lung infections caused by mycobacteria.

My research mainly focuses on evaluating and developing new treatments against tuberculosis (TB) and non-tuberculous mycobacterial infections. Specifically, I investigate how mycobacteria resist current treatments and aim to develop new therapies. My work includes optimizing new tuberculosis preventive treatments (TPT) for latent TB infections and characterizing new compounds and regimens against M. tuberculosis and NTM from the initial discovery (hit identification and hit-to-lead optimization) to pre-clinical studies.

Laboratory webpage (in construction)